---
layout: post
title: USAN Watch - August/September 2012
date: '2012-10-11T09:36:00.000+01:00'
author: John Overington
tags:
- INNS and USANS
modified_time: '2012-10-11T09:38:40.844+01:00'
thumbnail: http://3.bp.blogspot.com/-4fr-AOyvk_4/Trz_ix_nKaI/AAAAAAAABXk/qOg_xmhEf3I/s72-c/inns+and+usans.png
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-2048864231885341620
blogger_orig_url: http://chembl.blogspot.com/2012/10/usan-watch-augustseptember-2012.html
---

<div class="separator" style="clear: both; text-align: center;">
<a href="http://3.bp.blogspot.com/-4fr-AOyvk_4/Trz_ix_nKaI/AAAAAAAABXk/qOg_xmhEf3I/s1600/inns+and+usans.png"><img border="0" src="http://3.bp.blogspot.com/-4fr-AOyvk_4/Trz_ix_nKaI/AAAAAAAABXk/qOg_xmhEf3I/s1600/inns+and+usans.png" /></a></div>
<span class="Apple-style-span" style="font-family: inherit;">The USANs for August and September 2012 have recently been published. Sorry for being slow in posting these.... structures will appear over the next few days, and if anyone has the research codes for the various Merck compounds in this list, please post in the comments (telmapitant, vibregon and tildrakizumab).</span><br />
<br />
<table border="1"><tbody>
<tr><td><b>USAN</b></td><td><b>Research Code</b></td><td><b>Structure</b></td><td><b>Drug Class</b></td><td><b>Therapeutic class</b></td><td><b>Target</b></td></tr>
<tr><td><a href="http://www.ama-assn.org/resources/doc/usan/aldoxorubicin.pdf" target="_blank">aldoxorubicin</a>, <a href="http://www.ama-assn.org/resources/doc/usan/aldoxorubicin-hydrochloride.pdf" target="_blank">aldoxorubicin hydrochloride</a></td><td>INNO-206</td><td></td><td>natural product-derived small molecule</td><td>therapeutic</td><td>topoisomerase II</td></tr>
<tr><td><a href="http://www.ama-assn.org/resources/doc/usan/belnacasan.pdf" target="_blank">belnacasan </a></td><td>VX-765</td><td></td><td>synthetic small molecule</td><td>therapeutic</td><td>ICE-1</td></tr>
<tr><td><a href="http://www.ama-assn.org/resources/doc/usan/deferitazole.pdf" target="_blank">deferitazole</a>, <a href="http://www.ama-assn.org/resources/doc/usan/deferitazole-magnesium.pdf" target="_blank">deferitazole magnesium</a></td><td>FBS-071, SPD-602</td><td></td><td>synthetic small molecule</td><td>therapeutic</td><td>n/a</td></tr>
<tr><td><a href="http://www.ama-assn.org/resources/doc/usan/delparantag.pdf" target="_blank">delparantag</a>, <a href="http://www.ama-assn.org/resources/doc/usan/delparantag-pentahydrochloride.pdf" target="_blank">delparantag pentahydrochloride</a></td><td>PMX-60056</td><td></td><td>synthetic small molecule</td><td>therapeutic</td><td>heparin</td></tr>
<tr><td><a href="http://www.ama-assn.org/resources/doc/usan/dupilumab.pdf" target="_blank">dupilumab </a></td><td><div class="page" title="Page 1">
<div class="layoutArea">
<div class="column">
<span style="font-size: 12pt;"><span style="font-family: inherit;">REGN-668, SAR-231893&nbsp;</span></span></div>
</div>
</div>
</td><td></td><td>mAb</td><td>therapeutic</td><td>IL4R-alpha</td></tr>
<tr><td><a href="http://www.ama-assn.org/resources/doc/usan/elosulfase-alfa.pdf" target="_blank">elosulfase alfa </a></td><td><div class="page" title="Page 1">
<div class="layoutArea">
<div class="column">
<span style="font-family: inherit;"><span style="font-size: 12pt;">BMN 110, rhGALNS,&nbsp;</span><span style="font-size: 12pt; font-style: italic;">N</span><span style="font-size: 12pt;">-acetylgalactosamine-6-sulfatase, &nbsp;chondroitinsulfatase, galactose-6-sulfate</span></span><br />
<span style="font-family: inherit;"><span style="font-size: 12pt;">sulfatase, EC=3.1.6.4</span><span style="font-size: 12pt;">&nbsp;</span></span></div>
</div>
</div>
</td><td></td><td>enzyme</td><td>therapeutic</td><td>n/a</td></tr>
<tr><td><a href="http://www.ama-assn.org/resources/doc/usan/emixustat.pdf" target="_blank">emixustat</a>, <a href="http://www.ama-assn.org/resources/doc/usan/emixustat-hydrochloride.pdf" target="_blank">emixustat hydrochloride</a></td><td>ACU-4429</td><td></td><td>synthetic small molecule</td><td>therapeutic</td><td>RPE-65</td></tr>
<tr><td><a href="http://www.ama-assn.org/resources/doc/usan/empagliflozin.pdf" target="_blank">empagliflozin</a>&nbsp;</td><td><div class="page" title="Page 1">
<div class="layoutArea">
<div class="column">
<span style="font-size: 12pt;"><span style="font-family: inherit;">BI-10773&nbsp;</span></span></div>
</div>
</div>
</td><td></td><td>synthetic small molecule</td><td>therapeutic</td><td>SGLT2</td></tr>
<tr><td><a href="http://www.ama-assn.org/resources/doc/usan/entolimod.pdf" target="_blank">entolimod</a></td><td>CBLB-502</td><td></td><td>protein</td><td>therapeutic</td><td>TLR5</td></tr>
<tr><td><a href="http://www.ama-assn.org/resources/doc/usan/eravacycline.pdf" target="_blank">eravacycline</a>&nbsp;</td><td>TP-434</td><td></td><td>synthetic small molecule</td><td>therapeutic</td><td>30S ribosome</td></tr>
<tr><td><a href="http://www.ama-assn.org/resources/doc/usan/evodenoson.pdf" target="_blank">evodenoson </a></td><td><div class="page" title="Page 1">
<div class="layoutArea">
<div class="column">
<span style="font-size: 12pt;"><span style="font-family: inherit;">ATL313, DE-112&nbsp;</span></span></div>
</div>
</div>
</td><td></td><td>synthetic small molecule</td><td>therapeutic</td><td>A2A</td></tr>
<tr><td><a href="http://www.ama-assn.org/resources/doc/usan/filorexant.pdf" target="_blank">filorexant </a></td><td></td><td></td><td></td><td>therapeutic</td><td></td></tr>
<tr><td><a href="http://www.ama-assn.org/resources/doc/usan/gandotinib.pdf" target="_blank">gandotinib </a></td><td><div class="page" title="Page 1">
<div class="layoutArea">
<div class="column">
<span style="font-family: 'Helvetica'; font-size: 12.000000pt;">LY-2784544&nbsp;</span></div>
</div>
</div>
</td><td></td><td>synthetic small molecule</td><td>therapeutic</td><td>JAK2</td></tr>
<tr><td><br /></td><td></td><td></td><td></td><td><br /></td><td></td></tr>
<tr><td><a href="http://www.ama-assn.org/resources/doc/usan/ilorasertib.pdf" target="_blank">ilorasertib </a></td><td>ABT-348, A-968660</td><td></td><td>synthetic small molecule</td><td>therapeutic</td><td>AUR VEGFR SRC</td></tr>
<tr><td><a href="http://www.ama-assn.org/resources/doc/usan/lusutrombopag.pdf" target="_blank">lusutrombopag</a></td><td>S-888711</td><td></td><td>synthetic small molecule</td><td>therapeutic</td><td></td></tr>
<tr><td><a href="http://www.ama-assn.org/resources/doc/usan/mericitabine.pdf" target="_blank">mericitabine </a></td><td><div class="page" title="Page 1">
<div class="layoutArea">
<div class="column">
<span style="font-family: inherit;">RO5024048, &nbsp;R7128&nbsp;</span></div>
</div>
</div>
</td><td><br /></td><td>synthetic small molecule</td><td>therapeutic</td><td>HCV NS5B polymerase</td></tr>
<tr><td><a href="http://www.ama-assn.org/resources/doc/usan/nelipepimut-S.pdf" target="_blank">nelipepimut-s </a></td><td>E75 peptide</td><td><br /></td><td>peptide vaccine</td><td>therapeutic</td><td>HER2</td></tr>
<tr><td><a href="http://www.ama-assn.org/resources/doc/usan/nesvacumab.pdf" target="_blank">nesvacumab </a></td><td><div class="page" title="Page 1">
<div class="layoutArea">
<div class="column">
<span style="font-size: 12pt;"><span style="font-family: inherit;">REGN-910&nbsp;</span></span></div>
</div>
</div>
</td><td></td><td>mAb</td><td>therapeutic</td><td>angiopoeitin 2</td></tr>
<tr><td><a href="http://www.ama-assn.org/resources/doc/usan/ozanezumab.pdf" target="_blank">ozanezumab </a></td><td><div class="page" title="Page 1">
<div class="layoutArea">
<div class="column">
<span style="font-size: 12pt;"><span style="font-family: inherit;">GSK-1223249&nbsp;</span></span></div>
</div>
</div>
</td><td></td><td>mAb</td><td>therapeutic</td><td>Nogo-A</td></tr>
<tr><td><a href="http://www.ama-assn.org/resources/doc/usan/peginesatide.pdf" target="_blank">peginesatide</a>, <a href="http://www.ama-assn.org/resources/doc/usan/peginesatide-acetate.pdf" target="_blank">peginesatide acetate </a></td><td>AS-37702, Omontys</td><td></td><td>peptide</td><td>therapeutic</td><td>EPOr</td></tr>
<tr><td><a href="http://www.ama-assn.org/resources/doc/usan/peginterferon-beta-1a.pdf" target="_blank">peginterferon beta-1a</a> </td><td>BIIB-017</td><td></td><td>protein</td><td>therapeutic</td><td>IFNAR</td></tr>
<tr><td><a href="http://www.ama-assn.org/resources/doc/usan/pidilizumab.pdf" target="_blank">pidilizumab </a></td><td>CT-011</td><td></td><td>mAb</td><td>therapeutic</td><td>PD1</td></tr>
<tr><td><a href="http://www.ama-assn.org/resources/doc/usan/pimasertib.pdf" target="_blank">pimasertib </a></td><td><div class="page" title="Page 1">
<div class="layoutArea">
<div class="column">
<br />
<div class="page" title="Page 1">
<div class="layoutArea">
<div class="column">
<span style="font-size: 12pt;"><span style="font-family: inherit;">MSC1936369A; AS703026; EMD 1036239&nbsp;</span></span></div>
</div>
</div>
<br /></div>
</div>
</div>
</td><td></td><td>synthetic small molecule</td><td>therapeutic</td><td>MEK</td></tr>
<tr><td><a href="http://www.ama-assn.org/resources/doc/usan/ramucirumab.pdf" target="_blank">ramucirumab </a></td><td>IMC1121B</td><td></td><td>mAb</td><td>therapeutic</td><td>VEGFR2</td></tr>
<tr><td><a href="http://www.ama-assn.org/resources/doc/usan/rebastinib.pdf" target="_blank">rebastinib</a>, <a href="http://www.ama-assn.org/resources/doc/usan/rebastinib-tosylate.pdf" target="_blank">rebastinib tosylate </a></td><td><div class="page" title="Page 1">
<div class="layoutArea">
<div class="column">
<span style="font-size: 12pt;"><span style="font-family: inherit;">DP-1919.TO, DCC-2036&nbsp;</span></span></div>
</div>
</div>
</td><td></td><td>synthetic small molecule</td><td>therapeutic</td><td>Tie2 TrkA</td></tr>
<tr><td><a href="http://www.ama-assn.org/resources/doc/usan/riociguat.pdf" target="_blank">riociguat </a></td><td><div class="page" title="Page 1">
<div class="layoutArea">
<div class="column">
<span style="font-size: 12pt;"><span style="font-family: inherit;">BAY 63-2521&nbsp;</span></span></div>
</div>
</div>
</td><td></td><td>synthetic small molecule</td><td>therapeutic</td><td>soluble guanylate cyclase</td></tr>
<tr><td><a href="http://www.ama-assn.org/resources/doc/usan/sofosbuvir.pdf" target="_blank">sofosbuvir </a></td><td><div class="page" title="Page 1">
<div class="layoutArea">
<div class="column">
<span style="font-size: 12pt;"><span style="font-family: inherit;">PSI-7977 GS-7977</span></span></div>
</div>
</div>
</td><td></td><td>synthetic small molecule prodrug</td><td>therapeutic</td><td>HCV pol</td></tr>
<tr><td><a href="http://www.ama-assn.org/resources/doc/usan/telmapitant.pdf" target="_blank">telmapitant </a></td><td></td><td></td><td>synthetic small molecule</td><td>therapeutic</td><td></td></tr>
<tr><td><a href="http://www.ama-assn.org/resources/doc/usan/tenofovir-alafenamide.pdf" target="_blank">tenofovir alafenamide</a></td><td>GS-7340</td><td></td><td>synthetic small molecule prodrug</td><td>therapeutic</td><td>HIV-1 RT</td></tr>
<tr><td><a href="http://www.ama-assn.org/resources/doc/usan/tergenpumatucel-l.pdf" target="_blank">tergenpumatucel-L </a></td><td>HAL</td><td></td><td>cell</td><td>therapeutic</td><td>n/a</td></tr>
<tr><td><a href="http://www.ama-assn.org/resources/doc/usan/tildrakizumab.pdf" target="_blank">tildrakizumab</a></td><td></td><td></td><td>mAb</td><td>therapeutic</td><td>IL-23</td></tr>
<tr><td><a href="http://www.ama-assn.org/resources/doc/usan/ulosedine.pdf" target="_blank">ulodesine</a>, <a href="http://www.ama-assn.org/resources/doc/usan/ulosedine-succinate.pdf" target="_blank">ulodesine succinate </a></td><td><div class="page" title="Page 1">
<div class="layoutArea">
<div class="column">
<span style="font-size: 12pt;"><span style="font-family: inherit;">BCX-4208&nbsp;</span></span></div>
</div>
</div>
</td><td></td><td>synthetic small molecule</td><td>therapeutic</td><td>purine nucleoside phosphorylase (PNP)</td></tr>
<tr><td><a href="http://www.ama-assn.org/resources/doc/usan/vibegron.pdf" target="_blank">vibegron</a></td><td></td><td></td><td>synthetic small molecule</td><td>therapeutic</td><td></td></tr>
</tbody></table>
